SYK
Bearish signalScored 2026-10-18 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Stryker Corporation
- Nom
- Stryker Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $117.6B
- Employés
- 56,000
- PDG
- Kevin A. Lobo
- Site web
- https://www.stryker.com
- Marché
- ATECCNMDENOVGMEDIARTMDT
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$277,787
Avg sell (VWAP, 90d window) $336.30 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-18 17:07:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | King Debra | Sell · S | 826 | $336.30 | $277,787 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-09-11 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-22 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-06-02 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-23 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-12-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-20 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-16 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-12 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-08-25 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-31 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-06-26 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-04-17 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-03-13 | Jefferson Shreve | Sale (Partial) | $50,001 - $100,000 |
| 2025-02-26 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-10-02 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-12 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-12 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-17 | Michael C. Burgess | Sale (Full) | $15,001 - $50,000 |
| 2023-02-24 | Michael C. Burgess | Purchase | $1,001 - $15,000 |
| 2023-02-24 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2023-02-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-27 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2023-01-10 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2023-01-03 | Michael C. Burgess | Sale (Full) | $100,001 - $250,000 |
| 2022-12-30 | Michael C. Burgess | Sale (Full) | $100,001 - $250,000 |
| 2022-11-29 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-11-28 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-10-25 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-10-24 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-31 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-12 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-22 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-07-22 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-05-24 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-23 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-18 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-04-18 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-03-21 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-03-21 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-23 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-06 | Richard Ray Larsen | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-18 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Stryker's solid financial health (liquidity 75, fundamentals 65) and consistent cash flow generation provide a stable operational foundation, but the extremely low catalyst score (15) driven by active securities fraud…
The first sentence of the analysis written for SYK on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.89 · operating margin 19%
Recent news
- 2026-10-15 Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company''s possible violations of the federal securities laws.
- 2026-10-15 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-10-15 Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
- 2026-10-14 Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company''s possible violations of federal securities laws.
- 2026-10-14 Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
- 2026-10-13 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-10-13 Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter''s cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.
- 2026-10-08 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-10-08 The Monopolistic Razor-and-Blade Engine I Can’t Stop Buying A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
- 2026-10-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.0% | 64.4% | 61.0% | 59.8% | 62.6% | |
| Ebit Margin | 20.4% | 21.9% | 19.7% | 16.4% | 15.3% | |
| Ebitda Margin | 25.1% | 26.6% | 24.7% | 21.8% | 21.1% | |
| Operating Profit Margin | 19.5% | 16.3% | 20.9% | 20.2% | 22.0% | |
| Pretax Profit Margin | 18.0% | 15.5% | 17.9% | 14.5% | 13.3% | |
| Continuous Operations Profit Margin | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | |
| Net Profit Margin | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | |
| Bottom Line Profit Margin | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | |
| Current Ratio | 1.893 | 1.949 | 1.580 | 1.630 | 2.202 | |
| Quick Ratio | 1.212 | 1.323 | 0.969 | 0.996 | 1.474 | |
| Solvency Ratio | 0.175 | 0.181 | 0.197 | 0.166 | 0.151 | |
| Cash Ratio | 0.515 | 0.480 | 0.375 | 0.293 | 0.647 | |
| Price To Earnings Ratio | 41.398 | 45.808 | 35.906 | 39.244 | 50.552 | |
| Price To Earnings Growth Ratio | 5.165 | -7.959 | 1.060 | 2.209 | 2.091 | |
| Forward Price To Earnings Growth Ratio | 5.165 | -7.959 | 1.060 | 2.209 | 2.091 | |
| Price To Earnings Diluted Ratio | 41.842 | 46.398 | 36.298 | 39.626 | 51.230 | |
| Price To Earnings Diluted Growth Ratio | 5.073 | -7.812 | 1.077 | 2.177 | 2.109 | |
| Price To Book Ratio | 5.992 | 6.648 | 6.114 | 5.565 | 6.777 | |
| Price To Sales Ratio | 5.348 | 6.071 | 5.546 | 5.012 | 5.893 | |
| Price To Free Cash Flow Ratio | 31.364 | 39.340 | 36.248 | 45.416 | 36.822 | |
| Price To Operating Cash Flow Ratio | 26.632 | 32.338 | 30.632 | 35.239 | 30.897 | |
| Debt To Assets Ratio | 0.342 | 0.329 | 0.338 | 0.367 | 0.373 | |
| Debt To Equity Ratio | 0.730 | 0.684 | 0.726 | 0.814 | 0.867 | |
| Debt To Capital Ratio | 0.422 | 0.406 | 0.421 | 0.449 | 0.464 | |
| Long Term Debt To Capital Ratio | 0.399 | 0.371 | 0.370 | 0.416 | 0.456 | |
| Financial Leverage Ratio | 2.134 | 2.083 | 2.147 | 2.220 | 2.328 | |
| Working Capital Turnover Ratio | 3.539 | 3.821 | 4.784 | 3.909 | 3.376 | |
| Operating Cash Flow Ratio | 0.647 | 0.557 | 0.469 | 0.416 | 0.717 | |
| Operating Cash Flow Sales Ratio | 0.201 | 0.188 | 0.181 | 0.142 | 0.191 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.849 | 0.822 | 0.845 | 0.776 | 0.839 | |
| Debt Service Coverage Ratio | 2.867 | 2.826 | 1.754 | 2.240 | 7.283 | |
| Interest Coverage Ratio | 8.054 | 9.316 | 12.025 | 11.080 | 11.166 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.375 | 2.731 | 1.659 | 2.000 | 27.420 | |
| Operating Cash Flow Coverage Ratio | 0.308 | 0.300 | 0.275 | 0.194 | 0.253 | |
| Capital Expenditure Coverage Ratio | 6.628 | 5.619 | 6.454 | 4.463 | 6.215 | |
| Dividend Paid And Capex Coverage Ratio | 2.467 | 2.149 | 2.165 | 1.601 | 2.212 | |
| Dividend Payout Ratio | 0.396 | 0.407 | 0.360 | 0.446 | 0.476 | |
| Enterprise Value Multiple | 23.231 | 24.583 | 24.560 | 25.920 | 30.702 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.0% | ▼-0.4% | ▲1.6% |
| Ebit Margin | 20.4% | ▼-1.5% | ▲1.7% |
| Ebitda Margin | 25.1% | ▼-1.4% | ▲1.3% |
| Operating Profit Margin | 19.5% | ▲3.1% | ▼-0.3% |
| Pretax Profit Margin | 18.0% | ▲2.5% | ▲2.1% |
| Continuous Operations Profit Margin | 12.9% | ▼-0.3% | ▼-0.3% |
| Net Profit Margin | 12.9% | ▼-0.3% | ▼-0.3% |
| Bottom Line Profit Margin | 12.9% | ▼-0.3% | ▼-0.3% |
| Current Ratio | 1.893 | ▼-0.056 | ▲0.042 |
| Quick Ratio | 1.212 | ▼-0.111 | ▲0.017 |
| Solvency Ratio | 0.175 | ▼-0.006 | ▲0.001 |
| Cash Ratio | 0.515 | ▲0.035 | ▲0.053 |
| Price To Earnings Ratio | 41.398 | ▼-4.410 | ▼-1.184 |
| Price To Earnings Growth Ratio | 5.165 | ▲13.124 | ▲4.652 |
| Forward Price To Earnings Growth Ratio | 5.165 | ▲13.124 | ▲4.652 |
| Price To Earnings Diluted Ratio | 41.842 | ▼-4.556 | ▼-1.237 |
| Price To Earnings Diluted Growth Ratio | 5.073 | ▲12.885 | ▲4.548 |
| Price To Book Ratio | 5.992 | ▼-0.657 | ▼-0.227 |
| Price To Sales Ratio | 5.348 | ▼-0.723 | ▼-0.226 |
| Price To Free Cash Flow Ratio | 31.364 | ▼-7.976 | ▼-6.474 |
| Price To Operating Cash Flow Ratio | 26.632 | ▼-5.706 | ▼-4.516 |
| Debt To Assets Ratio | 0.342 | ▲0.013 | ▼-0.008 |
| Debt To Equity Ratio | 0.730 | ▲0.045 | ▼-0.035 |
| Debt To Capital Ratio | 0.422 | ▲0.016 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 0.399 | ▲0.027 | ▼-0.004 |
| Financial Leverage Ratio | 2.134 | ▲0.051 | ▼-0.048 |
| Working Capital Turnover Ratio | 3.539 | ▼-0.281 | ▼-0.346 |
| Operating Cash Flow Ratio | 0.647 | ▲0.090 | ▲0.086 |
| Operating Cash Flow Sales Ratio | 0.201 | ▲0.013 | ▲0.020 |
| Free Cash Flow Operating Cash Flow Ratio | 0.849 | ▲0.027 | ▲0.023 |
| Debt Service Coverage Ratio | 2.867 | ▲0.042 | ▼-0.527 |
| Interest Coverage Ratio | 8.054 | ▼-1.261 | ▼-2.274 |
| Short Term Operating Cash Flow Coverage Ratio | 4.375 | ▲1.643 | ▼-3.262 |
| Operating Cash Flow Coverage Ratio | 0.308 | ▲0.008 | ▲0.042 |
| Capital Expenditure Coverage Ratio | 6.628 | ▲1.010 | ▲0.752 |
| Dividend Paid And Capex Coverage Ratio | 2.466 | ▲0.318 | ▲0.348 |
| Dividend Payout Ratio | 0.396 | ▼-0.012 | ▼-0.021 |
| Enterprise Value Multiple | 23.231 | ▼-1.352 | ▼-2.568 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $134.33B | $137.18B | $113.68B | $92.47B | $100.82B | |
| Enterprise value | $146.68B | $147.65B | $124.20B | $104.15B | $110.77B | |
| EV / Sales | 5.84x | 6.54x | 6.06x | 5.64x | 6.47x | |
| EV / Op. cash flow | 29.08x | 34.81x | 33.47x | 39.69x | 33.95x | |
| EV / Free cash flow | 34.25x | 42.34x | 39.60x | 51.15x | 40.46x | |
| EV / EBITDA | 23.23x | 24.58x | 24.56x | 25.92x | 30.70x | |
| Net debt / EBITDA | 1.96x | 1.74x | 2.08x | 2.91x | 2.76x | |
| Current ratio | 1.89x | 1.95x | 1.58x | 1.63x | 2.20x | |
| Income quality | 1.55x | 1.42x | 1.17x | 1.11x | 1.64x | |
| Graham number | $106 | $98 | $96 | $79 | $69 | |
| Graham net-net | -$41 | -$33 | -$34 | -$36 | -$34 | |
| Tax burden | 71.9% | 85.7% | 86.2% | 87.9% | 87.4% | |
| Interest burden | 88.1% | 70.5% | 91.2% | 88.8% | 87.1% | |
| Working capital | $6.96B | $7.23B | $4.60B | $3.97B | $5.47B | |
| Invested capital | $36.33B | $31.45B | $28.14B | $27.18B | $26.48B | |
| Return on assets | 6.8% | 7.0% | 7.9% | 6.4% | 5.8% | |
| Operating ROA | 10.8% | 8.9% | 11.1% | 10.4% | 10.9% | |
| Return on tangible assets | 14.2% | 13.2% | 15.8% | 13.8% | 11.8% | |
| Return on equity | 14.5% | 14.5% | 17.0% | 14.2% | 13.4% | |
| Return on invested capital | 8.5% | 8.6% | 10.8% | 10.3% | 10.9% | |
| Return on capital employed | 12.2% | 10.4% | 13.4% | 12.2% | 12.5% | |
| Earnings yield | 2.4% | 2.2% | 2.8% | 2.6% | 2.0% | |
| Free cash flow yield | 3.2% | 2.5% | 2.8% | 2.2% | 2.7% | |
| Capex / Op. cash flow | 15.1% | 17.8% | 15.5% | 22.4% | 16.1% | |
| Capex / Depreciation | 63.8% | 71.9% | 55.9% | 58.9% | 53.0% | |
| Capex / Sales | 3.0% | 3.3% | 2.8% | 3.2% | 3.1% | |
| SG&A / Sales | 34.4% | 33.2% | 33.8% | 32.9% | 34.0% | |
| R&D / Sales | 6.3% | 6.5% | 6.3% | 6.7% | 6.6% | |
| Stock comp / Sales | 1.0% | 1.0% | 1.0% | 0.9% | 1.0% | |
| Intangibles / Total assets | 52.2% | 47.1% | 49.7% | 53.6% | 51.3% | |
| Days sales outstanding | 59d | 64d | 67d | 71d | 64d | |
| Days payables outstanding | 73d | 76d | 69d | 70d | 64d | |
| Operating cycle | 273d | 281d | 288d | 267d | 254d | |
| Cash conversion cycle | 200d | 205d | 219d | 198d | 189d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-2.1%EV / Sales ▼-10.6%EV / EBITDA ▼-5.5%EV / Op. cash flow ▼-5.726Earnings yield ▲+0.002Graham number ▲+8.036
Profitability
Return on equity -0.000Return on assets ▼-0.002Return on invested capital -0.000Return on capital employed ▲+0.018Operating ROA ▲+0.019Income quality ▲+0.137Tax burden ▼-0.138
Efficiency
Days sales outstanding ▼-5.709Days payables outstanding ▼-3.580Operating cycle ▼-8.033Cash conversion cycle ▼-4.453Capex / Sales ▼-0.003R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▼-0.056Net debt / EBITDA ▲+0.213Working capital ▼-270000000.000Invested capital ▲+4883000000.000Intangibles / Total assets ▲+0.051
Change over 5 years
Valuation
Market cap ▲+33.2%EV / Sales ▼-9.8%EV / EBITDA ▼-24.3%EV / Op. cash flow ▼-4.868Earnings yield ▲+0.004Graham number ▲+37.346
Profitability
Return on equity ▲+0.011Return on assets ▲+0.010Return on invested capital ▼-0.024Return on capital employed ▼-0.003Operating ROA ▼-0.001Income quality ▼-0.082Tax burden ▼-0.155
Efficiency
Days sales outstanding ▼-5.777Days payables outstanding ▲+8.150Operating cycle ▲+19.328Cash conversion cycle ▲+11.178Capex / Sales -0.000R&D / Sales ▼-0.003
Balance-sheet strength
Current ratio ▼-0.309Net debt / EBITDA ▼-0.804Working capital ▲+1493000000.000Invested capital ▲+9850000000.000Intangibles / Total assets ▲+0.009